STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

CollPlant Biotechnologies (Nasdaq: CLGN) announced it will report third quarter 2025 financial results on Wednesday, November 26, 2025, before the U.S. market open. The company develops non-animal-derived rhCollagen products for tissue regeneration and medical aesthetics. Investors can expect the company to release results and any accompanying commentary or materials on that date.

CollPlant Biotechnologies (Nasdaq: CLGN) ha annunciato che riferirà i risultati finanziari del terzo trimestre 2025 mercoledì 26 novembre 2025, prima dell'apertura del mercato statunitense. L'azienda sviluppa prodotti rhCollagen non derivati da animali per la rigenerazione dei tessuti e l'estetica medica. Gli investitori possono aspettarsi che l'azienda renda noti i risultati ed eventuali commenti o materiali correlati in quella data.

CollPlant Biotechnologies (Nasdaq: CLGN) anunció que informará los resultados financieros del tercer trimestre de 2025 el miércoles 26 de noviembre de 2025, antes de la apertura del mercado estadounidense. La empresa desarrolla productos rhCollagen no derivados de animales para la regeneración de tejidos y la estética médica. Los inversores pueden esperar que la empresa publique los resultados y cualquier comentario o material adjunto ese día.

CollPlant Biotechnologies (Nasdaq: CLGN)2025년 3분기 재무 실적2025년 11월 26일 수요일 미국 시장 개장 전에 발표할 예정이라고 발표했습니다. 회사는 동물 유래가 없는 rhCollagen 제품을 조직 재생 및 의료 미용을 위한 분야에서 개발합니다. 투자자들은 그 날짜에 회사가 결과와 함께 제공될 모든 해설이나 자료를 발표할 것으로 기대할 수 있습니다.

CollPlant Biotechnologies (Nasdaq: CLGN) a annoncé qu'elle publiera les résultats financiers du troisième trimestre 2025 le mercredi 26 novembre 2025, avant l'ouverture du marché américain. L'entreprise développe des produits rhCollagen non dérivés d'origine animale pour la régénération tissulaire et l'esthétique médicale. Les investisseurs peuvent s'attendre à ce que l'entreprise publie les résultats et tout commentaire ou matériel associé à cette date.

CollPlant Biotechnologies (Nasdaq: CLGN) gab bekannt, dass es die Finanzergebnisse des dritten Quartals 2025 am Mittwoch, dem 26. November 2025 vor der US-Handelsöffnung berichten wird. Das Unternehmen entwickelt rhCollagen-Produkte, die nicht tierischen Ursprungs sind für Gewebe regeneration und medizinische Ästhetik. Investoren können erwarten, dass das Unternehmen zu diesem Datum Ergebnisse sowie entsprechende Begleitkommentare oder Unterlagen veröffentlicht.

CollPlant Biotechnologies (ناسداك: CLGN) أعلنت أنها ستعلن عن نتائجها المالية للربع الثالث من عام 2025 يوم الأربعاء 26 نوفمبر 2025، قبل افتتاح السوق الأمريكية. تطور الشركة منتجات rhCollagen غير المشتقة من الحيوانات لإعادة تشكيل الأنسجة والجمالية الطبية. يمكن للمستثمرين توقع أن تقوم الشركة بنشر النتائج وأي تعليقات أو مواد مرافقة في ذلك التاريخ.

Positive
  • None.
Negative
  • None.

REHOVOT, Israel, Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 26, 2025, before the opening of the U.S. financial markets.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.

For more information about CollPlant, visit http://www.collplant.com

Contacts

CollPlant:
Eran Rotem   
Deputy CEO & CFO
Tel: +972-73-2325600
Email: eran@collplant.com  

Investors:
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com 

Cision View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-date-for-2025-third-quarter-financial-results-302618450.html

SOURCE CollPlant

FAQ

When will CollPlant (CLGN) report Q3 2025 results?

CollPlant will report Q3 2025 results on November 26, 2025, before the U.S. market opens.

What time will CollPlant (CLGN) release its November 26, 2025 results?

The company said results will be released before the U.S. market open on November 26, 2025.

How can investors access CollPlant (CLGN) Q3 2025 financial results?

Investors should check CollPlant investor relations and Nasdaq filings on November 26, 2025 for the full release.

Will CollPlant (CLGN) provide a conference call with the Q3 2025 results?

The announcement only scheduled the results release for November 26, 2025; any call or webcast was not specified.

What does CollPlant (CLGN) make and how is it described in the announcement?

CollPlant develops non-animal-derived rhCollagen technologies and products for tissue regeneration and medical aesthetics.
Collplant Biotechnologies Ltd

NASDAQ:CLGN

CLGN Rankings

CLGN Latest News

CLGN Latest SEC Filings

CLGN Stock Data

27.09M
8.60M
10.16%
12.23%
0.33%
Biotechnology
Healthcare
Link
Israel
Rehovot